Arthur He
Stock Analyst at HC Wainwright & Co.
(0.62)
# 3,707
Out of 4,810 analysts
60
Total ratings
21.82%
Success rate
-31.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Reiterates: Buy | $8 | $1.60 | +400.00% | 10 | Apr 3, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Buy | $3.5 → $3 | $0.25 | +1,102.40% | 6 | Apr 1, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $0.32 | - | 8 | Mar 31, 2025 | |
| LVTX LAVA Therapeutics | Reiterates: Neutral | $1.5 | $1.14 | +31.58% | 10 | Mar 31, 2025 | |
| PRME Prime Medicine | Reiterates: Buy | $10 | $1.32 | +657.58% | 7 | Mar 19, 2025 | |
| NKTR Nektar Therapeutics | Reiterates: Buy | $6.5 | $0.63 | +924.11% | 3 | Mar 13, 2025 | |
| SLDB Solid Biosciences | Maintains: Buy | $16 → $20 | $2.70 | +640.74% | 9 | Mar 10, 2025 | |
| HOOK HOOKIPA Pharma | Downgrades: Neutral | n/a | $0.79 | - | 7 | Jan 10, 2025 |
Adagene
Apr 3, 2025
Reiterates: Buy
Price Target: $8
Current: $1.60
Upside: +400.00%
Adaptimmune Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $0.25
Upside: +1,102.40%
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.32
Upside: -
LAVA Therapeutics
Mar 31, 2025
Reiterates: Neutral
Price Target: $1.5
Current: $1.14
Upside: +31.58%
Prime Medicine
Mar 19, 2025
Reiterates: Buy
Price Target: $10
Current: $1.32
Upside: +657.58%
Nektar Therapeutics
Mar 13, 2025
Reiterates: Buy
Price Target: $6.5
Current: $0.63
Upside: +924.11%
Solid Biosciences
Mar 10, 2025
Maintains: Buy
Price Target: $16 → $20
Current: $2.70
Upside: +640.74%
HOOKIPA Pharma
Jan 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.79
Upside: -